Patents by Inventor Jasdeep MANN
Jasdeep MANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260159820Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene. The present disclosure relates to genome editing compositions with improved stability and activity. More particularly, the disclosure relates to improved nuclease variants, compositions, and methods of using the same for editing the human program cell death (PDCD-1) gene.Type: ApplicationFiled: February 12, 2026Publication date: June 11, 2026Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Jordan JARJOUR, Kyle HAVENS, Jasdeep MANN
-
Patent number: 12590136Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: GrantFiled: May 7, 2020Date of Patent: March 31, 2026Assignees: Regeneron Pharmaceuticals, Inc., MEDIGENE IMMUNOTHERAPIES GMBHInventors: Jasdeep Mann, Christian Ellinger, Daniel Sommermeyer, Benjamin Boyerinas
-
Patent number: 12577547Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene.Type: GrantFiled: December 9, 2019Date of Patent: March 17, 2026Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jordan Jarjour, Kyle Havens, Jasdeep Mann
-
Publication number: 20250346648Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: ApplicationFiled: May 23, 2025Publication date: November 13, 2025Inventors: Christian Ellinger, Daniel Sommermeyer, Geoffrey Parsons, Jasdeep Mann
-
Patent number: 12391734Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.Type: GrantFiled: February 22, 2024Date of Patent: August 19, 2025Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jasdeep Mann, Joel Gay, Jordan Jarjour, Joy Zhang
-
Patent number: 12344654Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: GrantFiled: March 27, 2020Date of Patent: July 1, 2025Assignees: MEDIGENE IMMUNOTHERAPIES GMBH, Regeneron Pharmaceuticals, Inc.Inventors: Christian Ellinger, Daniel Sommermeyer, Geoffrey Parsons, Jasdeep Mann
-
Publication number: 20240301018Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.Type: ApplicationFiled: February 22, 2024Publication date: September 12, 2024Applicant: 2seventy bio, Inc.Inventors: Jasdeep MANN, Joel GAY, Jordan JARJOUR, Joy ZHANG
-
Patent number: 11912746Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.Type: GrantFiled: May 6, 2022Date of Patent: February 27, 2024Assignee: 2seventy bio, Inc.Inventors: Jasdeep Mann, Joel Gay, Jordan Jarjour, Joy Zhang
-
Publication number: 20230159612Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: ApplicationFiled: March 27, 2020Publication date: May 25, 2023Inventors: Christian ELLINGER, Daniel SOMMERMEYER, Geoffrey PARSONS, Jasdeep MANN
-
Publication number: 20230124640Abstract: The present disclosure provides improved T cell receptors, polynucleotides, polypeptides, vectors, cells, and methods f using the same.Type: ApplicationFiled: March 26, 2021Publication date: April 20, 2023Applicant: 2seventy bio, Inc.Inventor: JASDEEP MANN
-
Publication number: 20230044580Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: February 9, 2023Applicants: 2SEVENTY BIO, INC., MEDIGENE IMMUNOTHERAPIES GMBHInventors: JASDEEP MANN, CHRISTIAN ELLINGER, DANIEL SOMMERMEYER, BENJAMIN BOYERINAS
-
Publication number: 20220364123Abstract: The present disclosure provides improved genome editing compositions and methods for editing a human Wiskott-Aldrich syndrome gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of WAS, including but not limited to, an immune system disorder, thrombocytopenia, eczema, X-linked thrombocytopenia (XLT), or X-linked neutropenia (XLN).Type: ApplicationFiled: April 24, 2020Publication date: November 17, 2022Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Joel GAY, Iram F. KHAN, Jasdeep MANN, David J. RAWLINGS, Yupeng WANG
-
Publication number: 20220340626Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.Type: ApplicationFiled: May 6, 2022Publication date: October 27, 2022Applicant: 2seventy bio, Inc.Inventors: Jasdeep MANN, Joel GAY, Jordan JARJOUR, Joy ZHANG
-
Patent number: 11365226Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.Type: GrantFiled: September 8, 2017Date of Patent: June 21, 2022Assignee: 2seventy bio, Inc.Inventors: Jasdeep Mann, Joel Gay, Jordan Jarjour, Joy Zhang
-
Publication number: 20220177860Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene.Type: ApplicationFiled: December 9, 2019Publication date: June 9, 2022Applicant: 2Seventy bio, Inc.Inventors: JORDAN JARJOUR, KYLE HAVENS, JASDEEP MANN
-
Publication number: 20210040165Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.Type: ApplicationFiled: September 8, 2017Publication date: February 11, 2021Applicant: bluebird bio, Inc.Inventors: Jasdeep MANN, Joel GAY, Jordan JARJOUR, Joy ZHANG
-
Publication number: 20190184035Abstract: The present disclosure provides improved genome editing compositions and methods for editing a BCL11A gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.Type: ApplicationFiled: July 25, 2017Publication date: June 20, 2019Applicant: bluebird bio, Inc.Inventors: Jordan JARJOUR, Jasdeep MANN
